Cogent Biosciences (COGT) Q1 2026 earnings summary

Executive summary

• Focused on developing precision therapies for genetically defined diseases, with bezuclastinib as the lead candidate targeting Systemic Mastocytosis (SM) and gastrointestinal stromal tumors (GIST), and preparing for dual launches with two NDAs under FDA review and a third planned for 1H 2026.

• Positive top-line results from registrational trials for bezuclastinib in NonAdvSM, AdvSM, and GIST reported in 2025, with pivotal Phase 3 PEAK trial data in GIST selected for oral presentation at 2026 ASCO, leading to Breakthrough Therapy Designation and NDA submission under FDA RTOR program.

• NDA for bezuclastinib in NonAdvSM submitted December 2025, accepted by FDA in March 2026; PDUFA date set for December 30, 2026.

• Building internal commercial organization, targeting U.S. launch of bezuclastinib in H2 2026, pending approval, and initiated expanded access programs for bezuclastinib in GIST and SM.

• Pipeline includes early-stage programs targeting ErbB2, PI3Kα, KRAS, and JAK2 mutations, with Phase 1 studies and IND applications planned.

Financial highlights

• Net loss of $97.4 million for Q1 2026, compared to $72.0 million for Q1 2025.

• Research and development expenses increased to $75.4 million (Q1 2026) from $63.0 million (Q1 2025), driven by pipeline advancement, higher personnel costs, and one-time FGFR program wind-down costs.

• General and administrative expenses rose to $28.2 million (Q1 2026) from $11.9 million (Q1 2025), reflecting commercial build-out and organizational growth.

• Cash, cash equivalents, and marketable securities totaled $866.4 million as of March 31, 2026, including $45.7 million from ATM stock offering and $18.0 million in non-recurring payments.

• Operating expenses totaled $103.6 million in Q1 2026, up from $74.9 million in Q1 2025.

Outlook and guidance

• Cash position expected to fund operations into 2028, including through potential FDA approval and commercial launch of bezuclastinib.

• NDA submission for AdvSM planned for 1H 2026; GIST NDA submitted March 2026 under RTOR.

• Pending FDA approvals, expects to launch bezuclastinib in SM and GIST in 2H 2026.

• Anticipates increased expenses as commercialization and clinical development activities expand.